How can the BioE3 Policy turn India's biotechnology startup base into a biomanufacturing powerhouse?
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →On 24 August 2024 the Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment and Employment) Policy. It aims to set up biomanufacturing hubs, Bio-AI hubs and biofoundries [1]. India's bioeconomy reached USD 195.3 billion in 2025, about 4.8% of GDP [2]. The country also has more than 11,000 biotech startups [3]. The problem is not the number of startups. It is their scale: most never get from lab to factory. BioE3 can close that gap.
Why startups stay small
- Scale-up costs: pilot plants and fermentation capacity are costly to build, so most startups never get beyond proof-of-concept.
- Thin private capital: private-sector R&D has stayed at about 0.25% of GDP [4].
- The translation gap: taking research to market needs capital, mentorship and industry partners [3].
How BioE3 can bridge the gap
- Shared infrastructure: startups can scale up in biomanufacturing hubs without building their own plants [1].
- Faster design: biofoundries and Bio-AI hubs shorten the design-build-test cycle [1].
- Focused demand: six priority sectors give clear targets. Examples are bio-based chemicals, smart proteins, precision biotherapeutics and climate-resilient agriculture [1].
- Lab-to-market links: DBT has merged its institutes into BRIC, and BRIC's Entrepreneur-in-Residence programme helps turn lab discoveries into startups [3].
- Green advantage: links to Net Zero and LiFE help position Indian products for markets that prefer low-carbon supply chains [1].
Enablers still needed
- Finance: blended funds and public procurement to bring in private investors.
- Regulation: clear, time-bound approval routes for biomanufactured products.
- Talent: recruit the scientific diaspora through Vaibhav Connect [3].
- Metrics: track products licensed and startups scaled, not just papers published.
Momentum: the bioeconomy grew from USD 10 billion in 2014 [5]. The government targets USD 300 billion by 2030 [2] and USD 1 trillion by 2047 [3].
In short, BioE3 can turn a large but fragmented startup base into a manufacturing base by sharing infrastructure, targeting priority sectors and linking labs to markets. This only works if patient capital and faster regulation come with it. With those in place, biomanufacturing can drive Viksit Bharat 2047, creating jobs and green growth in line with SDG 9 (industry, innovation and infrastructure).
Sources
- 1PIB: Cabinet approves BioE3 Policy for Fostering High Performance Biomanufacturing (24 Aug 2024)approval date, hubs and biofoundries, six sectors, Net Zero and LiFE links
- 2PIB, Ministry of Science & Technology: India BioEconomy Report 2026 (19 Mar 2026)USD 195.3 bn in 2025, 4.8% of GDP, USD 300 bn target for 2030
- 3PIB: BRIC aims at USD 300 billion bioeconomy by 2030 and USD 1 trillion by 2047 (Fourth AGM, BRIC Society, 21 Nov 2026)11,000+ startups, translation needs, EiR, Vaibhav Connect, USD 1 tn target for 2047
- 4PRS Legislative Research: Demand for Grants 2024-25 Analysis, Science and Technologyprivate R&D stuck at about 0.25% of GDP
- 5PIB document (Sep 2025): India's bioeconomyUSD 10 bn in 2014